Cargando…

Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system

BACKGROUND: Immune-mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature data on patients with IMIDs undergoing pregnancy is scarce and often overlooks the impact of comorbidities. METHODS: We investigated 12 selected IMIDs: psoriasis, inflammatory bowe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Yeon Mi, Wei, Qi, Piekos, Samantha N., Vemuri, Bhargav, Molani, Sevda, Mease, Philip, Hood, Leroy, Hadlock, Jennifer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441487/
https://www.ncbi.nlm.nih.gov/pubmed/37609126
http://dx.doi.org/10.1101/2023.08.07.23293726
_version_ 1785093384741847040
author Hwang, Yeon Mi
Wei, Qi
Piekos, Samantha N.
Vemuri, Bhargav
Molani, Sevda
Mease, Philip
Hood, Leroy
Hadlock, Jennifer J.
author_facet Hwang, Yeon Mi
Wei, Qi
Piekos, Samantha N.
Vemuri, Bhargav
Molani, Sevda
Mease, Philip
Hood, Leroy
Hadlock, Jennifer J.
author_sort Hwang, Yeon Mi
collection PubMed
description BACKGROUND: Immune-mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature data on patients with IMIDs undergoing pregnancy is scarce and often overlooks the impact of comorbidities. METHODS: We investigated 12 selected IMIDs: psoriasis, inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, antiphospholipid syndrome, Sjögren’s syndrome, vasculitis, sarcoidosis, systemic sclerosis. We characterized patients with IMIDs prior to pregnancy (IMIDs group) based on pregnancy/maternal characteristics, comorbidities, and pre-pregnancy/prenatal immunomodulatory medications (IMMs) prescription patterns. We 1:1 propensity score matched the IMIDs cohort with people who had no IMID diagnoses prior to pregnancy (non-IMIDs cohort). Outcome measures were preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and cesarean section. FINDINGS: The prevalence rate of pregnancy occurring with people with a previous IMID diagnosis has doubled in the past ten years. We identified 5,784 patients with IMIDs. 17% of the IMIDs group had at least one prenatal IMM prescription. Depending on the type of IMM, from 48% to 70% of the patients taking IMMs before pregnancy continued them throughout pregnancy. Patients with IMIDs had similar but slightly increased risks of PTB (Relative risk (RR)=1·1[1·0, 1·3]), LBW (RR=1·2 [1·0,1·4]), SGA (RR=1·1 [1·0,1·2]), and cesarean section (RR=1·1 [1·1,1·2]) compared to a matched cohort of people without IMIDs. Out of the 12 selected IMIDs, three for PTB, one for LBW, two for SGA, and six for cesarean section had results supporting increased risk. INTERPRETATION: The association between IMIDs and the increased risk of adverse pregnancy outcomes depend on both the nature of the IMID and the presence of comorbidities.
format Online
Article
Text
id pubmed-10441487
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-104414872023-08-22 Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system Hwang, Yeon Mi Wei, Qi Piekos, Samantha N. Vemuri, Bhargav Molani, Sevda Mease, Philip Hood, Leroy Hadlock, Jennifer J. medRxiv Article BACKGROUND: Immune-mediated inflammatory diseases (IMIDs) are likely to complicate maternal health. However, literature data on patients with IMIDs undergoing pregnancy is scarce and often overlooks the impact of comorbidities. METHODS: We investigated 12 selected IMIDs: psoriasis, inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, antiphospholipid syndrome, Sjögren’s syndrome, vasculitis, sarcoidosis, systemic sclerosis. We characterized patients with IMIDs prior to pregnancy (IMIDs group) based on pregnancy/maternal characteristics, comorbidities, and pre-pregnancy/prenatal immunomodulatory medications (IMMs) prescription patterns. We 1:1 propensity score matched the IMIDs cohort with people who had no IMID diagnoses prior to pregnancy (non-IMIDs cohort). Outcome measures were preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and cesarean section. FINDINGS: The prevalence rate of pregnancy occurring with people with a previous IMID diagnosis has doubled in the past ten years. We identified 5,784 patients with IMIDs. 17% of the IMIDs group had at least one prenatal IMM prescription. Depending on the type of IMM, from 48% to 70% of the patients taking IMMs before pregnancy continued them throughout pregnancy. Patients with IMIDs had similar but slightly increased risks of PTB (Relative risk (RR)=1·1[1·0, 1·3]), LBW (RR=1·2 [1·0,1·4]), SGA (RR=1·1 [1·0,1·2]), and cesarean section (RR=1·1 [1·1,1·2]) compared to a matched cohort of people without IMIDs. Out of the 12 selected IMIDs, three for PTB, one for LBW, two for SGA, and six for cesarean section had results supporting increased risk. INTERPRETATION: The association between IMIDs and the increased risk of adverse pregnancy outcomes depend on both the nature of the IMID and the presence of comorbidities. Cold Spring Harbor Laboratory 2023-08-09 /pmc/articles/PMC10441487/ /pubmed/37609126 http://dx.doi.org/10.1101/2023.08.07.23293726 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Hwang, Yeon Mi
Wei, Qi
Piekos, Samantha N.
Vemuri, Bhargav
Molani, Sevda
Mease, Philip
Hood, Leroy
Hadlock, Jennifer J.
Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title_full Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title_fullStr Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title_full_unstemmed Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title_short Maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system
title_sort maternal-fetal outcomes in patients with immune mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large u.s. healthcare system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441487/
https://www.ncbi.nlm.nih.gov/pubmed/37609126
http://dx.doi.org/10.1101/2023.08.07.23293726
work_keys_str_mv AT hwangyeonmi maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT weiqi maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT piekossamanthan maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT vemuribhargav maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT molanisevda maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT measephilip maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT hoodleroy maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem
AT hadlockjenniferj maternalfetaloutcomesinpatientswithimmunemediatedinflammatorydiseaseswithconsiderationofcomorbiditiesaretrospectivecohortstudyinalargeushealthcaresystem